HIV reservoirs and the possibility of a cure for HIV infection (Q37935109)

25 August 2017

1 reference

title

HIV reservoirs and the possibility of a cure for HIV infection (English)

1 reference

25 August 2017

0 references

S Palmer

1

1 reference

25 August 2017

L Josefsson

series ordinal

2

1 reference

25 August 2017

J M Coffin

series ordinal

3

1 reference

25 August 2017

language of work or name

English

0 references

publication date

27 October 2011

1 reference

Journal of Internal Medicine

25 August 2017

1 reference

25 August 2017

270

1 reference

25 August 2017

6

1 reference

25 August 2017

550-560

1 reference

Prevalence and predictive value of intermittent viremia with combination hiv therapy

25 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

Predictors of residual viremia in HIV-infected patients successfully treated with efavirenz and lamivudine plus either tenofovir or stavudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

Decay characteristics of HIV-1-infected compartments during combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

HIV rebounds from latently infected cells, rather than from continuing low-level replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

Viral dynamics in human immunodeficiency virus type 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

Infection of monocyte/macrophages by human T lymphotropic virus type III.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

Long-term productive human immunodeficiency virus infection of CD1a-sorted myeloid dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

Characterization of nonlymphoid cells derived from rat peripheral lymph

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

Peripheral blood Dendritic cells are not a major reservoir for HIV type 1 in infected individuals on virally suppressive HAART.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

Persistence of infectious HIV on follicular dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

Short communication: dynamic constraints on the second phase compartment of HIV-infected cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

Analysis of human immunodeficiency virus type 1 viremia and provirus in resting CD4+ T cells reveals a novel source of residual viremia in patients on antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

Residual human immunodeficiency virus (HIV) Type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal fluid after suppression of viremia for 2 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

The immunopathogenesis of human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

Viral suppression and immune restoration in the gastrointestinal mucosa of human immunodeficiency virus type 1-infected patients initiating therapy during primary or chronic infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

Kinetics of HIV-1 in cerebrospinal fluid and serum after zidovudine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

HIV-1 associated dementia: update on pathological mechanisms and therapeutic approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

HIV-1-associated dementia during HAART therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

Antiretroviral therapy and central nervous system HIV type 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

Treatment intensification has no effect on the HIV-1 central nervous system infection in patients on suppressive antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

Epigenetic regulation of HIV-1 latency by cytosine methylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

HIV reservoirs, latency, and reactivation: prospects for eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

Resting CD4+ T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

HIV reproducibly establishes a latent infection after acute infection of T cells in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

Transcriptional interference antagonizes proviral gene expression to promote HIV latency

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

Cells nonproductively infected with HIV-1 exhibit an aberrant pattern of viral RNA expression: a molecular model for latency

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

CpG methylation controls reactivation of HIV from latency

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

Induction of HIV-1 latency and reactivation in primary memory CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

Establishment of HIV latency in primary CD4+ cells is due to epigenetic transcriptional silencing and P-TEFb restriction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

HIV integration site distributions in resting and activated CD4+ T cells infected in culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

The contribution of monocyte infection and trafficking to viral persistence, and maintenance of the viral reservoir in HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

Interleukin-7 induces expression of latent human immunodeficiency virus type 1 with minimal effects on T-cell phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

Depletion of latent HIV-1 infection in vivo: a proof-of-concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

Stability of the latent reservoir for HIV-1 in patients receiving valproic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

Combinatorial latency reactivation for HIV-1 subtypes and variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

High throughput drug screening for human immunodeficiency virus type 1 reactivating compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

Isolation of a cellular factor that can reactivate latent HIV-1 without T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

Hit-and-run stimulation: a novel concept to reactivate latent HIV-1 infection without cytokine gene induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

A simian immunodeficiency virus-infected macaque model to study viral reservoirs that persist during highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

Viral sanctuaries during highly active antiretroviral therapy in a nonhuman primate model for AIDS

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

Intrarectal transmission, systemic infection, and CD4+ T cell depletion in humanized mice infected with HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

Intravenous immunoglobulin: an update on the clinical use and mechanisms of action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02457.X

10.1111/J.1365-2796.2011.02457.X

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference